Background {#Sec1}
==========

Sepsis is a leading cause of mortality and critical illness worldwide \[[@CR1]\]. Recent reports have shown that patient mortality has been reduced, particularly when recommended bundles of care are applied \[[@CR2], [@CR3]\]. Nevertheless, the septic shock mortality rate still varies between 30 and 40% \[[@CR2], [@CR3]\]. In accordance with recent findings, there is growing interest in long-term sepsis outcomes. Sepsis is associated with an increased mortality rate in the months and years after hospital discharge \[[@CR4]\]. Observational studies have reported 1-year mortality rates greater than 50% after hospital discharge \[[@CR5]\]. The consequences of sepsis, therefore, are not limited to those observed during ICU stays. Post sepsis, patients are prone to decompensating or experiencing several diseases or organ dysfunction, such as cardiovascular disease \[[@CR6]--[@CR8]\], pulmonary disease \[[@CR9]\], renal disease \[[@CR10]\], depression and cognitive disabilities \[[@CR11]\], and immune dysfunction \[[@CR12]\]. These ailments lead to long-term decreased functional status \[[@CR13]\]. The occurrence of persistent or new organ(s) dysfunction(s) after septic shock raises questions about the cellular, metabolic and immune mechanisms involved in the post-sepsis status.

Potential mechanisms that alter long-term outcomes, such as persistence of altered innate immune and pro-coagulant responses to sepsis, have been previously described. These mechanisms have been studied through several mediators or molecules, such as C-reactive protein (CRP), tumor necrosis factor (TNFα), interleukin (IL)-6, IL-10, d-dimers, antithrombin-III, and factor IX, and the fibrinolytic pathway \[[@CR12], [@CR14]--[@CR16]\]. Another mechanism is the altered adaptive immune response, with depletion of naïve immune cells \[[@CR17]\]. Beside usual mediators like inflammatory cytokines, lipid mediators, and protein from the apoptosis cell death machinery, there is growing interest in metabolites involved in inflammation. Tryptophan (Trp) and its metabolites play an important role in the immune balance between response to pathogen and tolerance \[[@CR18]\].

The underlying mechanisms explaining the impact of the ICU stay on post-ICU outcomes remain unclear. Accordingly, the present study aimed to explore the natural evolution of the immune profile from ICU admission to 1 year later and to assess the relationship between this immune profile and 1e-year outcomes in ICU patients admitted with abdominal septic shock.

Method {#Sec2}
======

Study design {#Sec3}
------------

We conducted a single-center, prospective study in a surgical ICU at Lariboisière Hospital, a university hospital located in Paris, France. The main objective was to characterize the global variations in the immune and inflammatory status of patients with septic shock admitted to the ICU, for up to 1 year after hospital discharge, by studying the variations in their biomarkers. The secondary objective was to evaluate the prognostic impact of these biomarkers on patient outcomes. The protocol was approved by our institutional review board (IRB) (Comité d'Evaluation de l'Ethique des Projets de Recherche Biomédicale Paris Nord, IRB 00006477). All included patients were informed about the study, and written informed consent was obtained from all participants. If the patient was unable to be informed, the next of kin was informed and provided consent for the patient to participate.

Patient selection and data collection {#Sec4}
-------------------------------------

All consecutive patients admitted to the ICU with a diagnosis of septic shock of abdominal origin from February 2010 to May 2013 were enrolled. In all cases, the source was controlled by surgery. Septic shock was defined according to the criteria of the International Sepsis Definitions Conference \[[@CR19]\]. Patients younger than 18 years of age, pregnant patients, and patients with aplasia or immunosuppressive disease (e.g., HIV) or receiving immunosuppressive therapy (i.e., chemotherapy, chronic used of steroids, autoimmune disease treatment) were excluded from the study. None of the patients received steroids during their ICU stay. Note that these patients were included in another previously published study (86 of 130 patients) \[[@CR20]\]. The following demographic and clinical data were collected: age, sex, comorbidities (Charlson comorbidity index score) \[[@CR21]\], Simplified Acute Physiology Score II \[[@CR22]\], Sequential Organ Failure Assessment score \[[@CR23]\] at day 1, length of ICU stay, ICU mortality, post-ICU discharge mortality, and 1-year survival. We extracted marker measurements in 32 patients post orthopedic surgery, as a control group.

Studied biomarkers {#Sec5}
------------------

We studied 15 different plasma biomarkers measured at ICU admission, at ICU discharge in surviving patients, and at 1 year, and grouped within three different clusters. The first cluster was composed of inflammatory cytokines: TNFα, IL-6, interferon-γ (INF-γ), IL-17 and metabolites: L-kynurenine (Kyn), Trp, and indoleamine 2, 3 dioxygenase (IDO). The second cluster was composed of cell damage and apoptosis markers: uric acid, high mobility group Box 1 protein (HMGB1) and caspase-3 activity. Caspase-3 activity was chosen as a surrogate for pro-apoptotic balance. The third cluster was composed of markers of (1) immunosuppression with the programmed death-1 (PD-1) protein and (2) resolution of inflammation with two cytokines - IL-10 and IL-7 - and two plasma lipids that are pro-resolving mediators, resolvins 1 and 5 (RvD1 and RvD5) (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Laboratory procedures {#Sec6}
---------------------

Data collection was performed within (1) 24 h of the onset of shock, (2) on the day of ICU discharge, and (3) during an ambulatory care visit 12 to 18 months after ICU discharge.

The biomarker analyses were blinded. The plasma levels of IL-6, IL-7, IL-10, IL-17, IFN-γ and TNFα were measured using sandwich immunoassay methods with commercially available electrochemiluminescent detection systems, plates and reagents (V-PLEX human cytokine 30-Plex kits (Meso-Scale Discovery (MSD), Gaithersburg, USA), as per the manufacturer's instructions. Briefly, 50 μL of plasma was loaded per well in the MSD plates. The plates were analyzed using the SECTOR Imager 2400. Plasma Trp and Kyn levels were measured using high-performance liquid chromatography, as described by Kema et al. \[[@CR24]\] and Fujigaki et al. \[[@CR25]\], respectively. IDO (*EC* 1.13.11.52) activity was estimated with the Kyn/Trp ratio. Plasma lipid pro-resolving mediators (RvD1 and RvD5) were investigated using liquid chromatography-tandem mass spectrometry (LC-MS-MS), as described by Colas et al. \[[@CR26]\]. Caspase-3 activity was determined using the substrate DEVD-AFC in the presence or absence of the caspase-3 inhibitor Ac-DEVD-CHO (Calbiochem), as described by the manufacturer (Abcam). The caspase-3 activity was calculated by subtracting the activity in the presence of Ac-DEVD-CHO from the activity in its absence. The concentrations of circulating high mobility group box 1 (HMGB1) and soluble PD-1 (sPD-1) proteins were measured in plasma samples using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Shino-Test Corporation, Tokyo, Japan and R&D Systems, Minneapolis, MN, USA), according to the manufacturers' instructions. Finally, plasma uric acid was quantified by colorimetry (uricase assay) on an Architect C8000 clinical chemistry device (Abbott). For each assay, the samples were analyzed in triplicate and then compared with the known concentrations of protein standards, either external or added to the samples to account for any interfering product.

Statistical analysis {#Sec7}
--------------------

The results are expressed as the median (interquartile range (IQR)) or count (percentage), as appropriate. Two outcome measures were considered: in-ICU mortality in all patients and 1-year mortality in the in-ICU survivors. Comparisons were performed using the Wilcoxon signed-rank test or the chi-squared test, as appropriate. Correlation was assessed using Pearson's correlation coefficient. A *p* value \<0.05 was considered to be statistically significant. All statistical analyses were performed using the R statistical software (The "R" Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec8}
=======

Patients and outcome {#Sec9}
--------------------

Eighty-six patients with septic shock were enrolled in our study. Thirty-one patients (36%) died in the ICU. Of the 55 ICU survivors, 9 (16%) died in the following year. Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of the cohort. The origins of sepsis were primarily peritonitis, biliary diseases, and acute intestinal ischemia.Table 1Patients' characteristicsAll patients (*n* = 86)Age, years72 (62--81)Female gender41 (48%)Origin of abdominal sepsis Community-acquired/postoperative peritonitis26 (30%)/23 (27%) Acute biliary diseases: angiocholitis, biliary peritonitis14 (16%) Acute intestinal ischemia20 (23%) Miscellaneous3 (3%)Comorbidities Heart and vascular diseases23 (30%) COPD3 (3%) Cancer/immunosuppression19 (22%) Charlson comorbidity index score3 (2--4)Severity and outcome SAPS II50 (44--60) SOFA score at admission9 (7--12)In-ICU LOS (days)8 (4--17)In-ICU deaths31 (36%)In-hospital LOS (days)23 (8--47)Death at 1 year among ICU survivors9 (16%)Continuous variables are expressed as median (interquartile range) or count (percentage), as appropriate*Abbreviations*: *COPD* chronic obstructive pulmonary disease, *SAPS II* Simplified Acute Physiology Score II, *SOFA* Sequential Organ Failure Assessment, *ICU* intensive care unit, *LOS* length of stay

Biomarker profiles from onset to one year after septic shock {#Sec10}
------------------------------------------------------------

Values of biomarkers at admission, at discharge and at one year are depicted in Fig. [1](#Fig1){ref-type="fig"}. Table [2](#Tab2){ref-type="table"} summarizes the corresponding values compared to a control group and reports the proportion of patients outside the normal range for each biomarkers at the three timepoints.Fig. 1Biomarker profile at the onset of septic shock, at ICU discharge and up to one year following septic shock. **a** biomarkers of inflammation, **b** biomarkers of damage and apoptotic cells, **c** biomarkers of sepsis induced immunosuppression and resolution of inflammation. *TNF* tumor necrosis factor, *IL* interleukin, *IFN-γ*, interferon-γ, *IDO* indoleamine2,3 dioxygenase, *HMGB1* high mobility group box 1 protein, *PD* programmed cell death protein, *RvD* resolvinsTable 2Biomarkers levels at admission, ICU discharge, and at one yearControl group (*n* = 32)Admission (*n* = 86)Discharge (*n* = 55)One year (*n* = 46)*p* valueMedian (IQR)Proportion outside the normal range^a^Median (IQR)Proportion outside the normal range^a^Median (IQR)Proportion outside the normal range\*TNFα (pg/mL)23.8 (20.8--34.5)65 (41.2--95.5)78%35.2 (21--54)45%37.8 (32.2--44.5)33%\<0.0001IL-6 (pg/mL)5.7 (3.5--8.2)2289 (1487--3050)99%59 (30.5--83)91%15.2 (13.4--16.8)78%\<0.0001IFNɣ (pg/mL)9.1 (7.4--15.8)19.2 (17.1--27.1)34%10 (7.4--13.8)4%6.6 (4.2--8.3)0%\<0.0001IL-17 (pg/mL)19.5 (16.9--27.9)20.1 (16--28.5)5%70.8 (55.9--79.5)87%31.8 (29.8--40.9)2%\<0.0001Trp (μmol/L)45.5 (41.9--49.1)48.9 (39.7--60.8)74%35.7 (29.2--40.9)98%37 (31--44)89%\<0.0001IDO (%)3.9 (3.4--5.5)11.1 (8.5--15.6)87%13.5 (9.2--18.5)78%10.1 (7--15.1)63%\<0.0001Kyn (μmol/L)1.8 (1.5--2.5)5.6 (3.7--7.9)94%5.1 (3.4--6.1)91%3.3 (2.8--4.9)63%\<0.0001Uric acid (μmol/L)289 (254.8--326.5)323 (278.2--381)30%318 (274--397.2)33%321.5 (262--388)22%0.04HMGB-1 (ng/mL)6.7 (4--8)17.3 (16.1--18.9)94%7 (5.5--9.3)24%5.9 (5.2--8.9)15%0.61Caspase 3 (pmol/min/mL)0.5 (0.4--0.6)4.5 (2.2--7.6)83%3.8 (2.5--4.9)100%1.2 (0.4--1.8)48%0.01PD-1 (ng/mL)0.05 (0.04--0.10)0.04 (0.03--0.05)0%0.79 (0.56--1.03)95%0.15 (0.12--0.18)80%\<0.0001IL-10 (pg/mL)5.3 (3.8--6.5)6.1 (4.1--7.4)21%13.8 (11.6--15.5)91%5.8 (4.3--7.3)15%0.45RvD1 (pg/mL)3.5 (2.8--5.2)0.8 (0.4--1)0%5 (3.9--5.8)22%4.9 (4.1--6.1)26%0.002RvD5 (pg/mL)1.4 (0.6--1.5)0 (0--0)0%4.9 (4--6.1)95%1.1 (0.8--1.3)9%0.27IL-7 (pg/mL)0.6 (0.4--1.3)2.2 (1.2--3.2)56%5.8 (4.8--7.1)100%6.8 (5.7--7.4)89%\<0.0001Continuous variables are expressed as median (interquartile range); *p* values are from the Wilcoxon test comparing patients at 1 year with the control group*Abbreviations*: *TNFα* tumor necrosis factor alpha, *IL* interleukin, *IFN* interferon, *Trp* tryptophan, *Kyn* kynurenine, *IDO* indoleamine2,3 dioxygenase, *HMGB* high mobility group box 1 protein, *PD*-1, programmed death protein-1, *RvD* resolvins^a^Normal ranges were defined according to manufacturers' specifications as reported in Additional file [1](#MOESM1){ref-type="media"}: Table S1

### Biomarkers at admission {#Sec11}

At the onset of septic shock, we observed a cohesive pro-inflammatory profile. The primary findings were augmented levels of TNFα, IL-6, Kyn and IDO for the first cluster and HMGB1 and caspase 3 for the second cluster. Conversely, cluster 3 biomarkers, RvD1 and RvD5, were diminished.

### Biomarkers at discharge {#Sec12}

At the time of ICU discharge, the profile evolved, tending toward the resolution of the inflammation. Nevertheless, except for TNFα and IFN-γ, there were abnormal levels of all biomarkers of the inflammatory cluster. Pro-inflammatory mediators (IL-6, IL-17, Kyn and IDO) were elevated. Remarkably, the levels of IL-6 decreased compared to admission levels, whereas IL-17 increased.. The apoptotic biomarker, caspase-3, had decreased, but it was still abnormally high. Immunosuppression starts with increased PD-1, together with resolution of the inflammation process, as reflected in the elevated levels of IL-10, RvD1, RvD5, and IL-7.

### Biomarkers at one year {#Sec13}

At 1 year, there was no complete restoration of homeostasis. Several markers had persistent abnormal levels, while some had corrected and returned to normal levels. IL-6, Kyn, and IDO in cluster 1, caspase 3 for cluster 2 and PD-1 and IL-7 in cluster 3 were significantly elevated. Note that the PD-1 levels were above the normal range but were lower compared to the ICU discharge levels, while the IL-7 levels were consistent with those observed at discharge. Accordingly, the Trp level was below the normal range. The proportion of patients having at least one abnormal biomarker in only one cluster was 9% (n = 4), whereas 70% (n = 32) had abnormal values of biomarkers within all three clusters.

Regarding the difference between the measurements taken at ICU discharge and at 1-year follow-up, we identified two types of biomarkers of change: those associated with a significant decrease (i.e., PD-1, RvD5, IL-6, caspase 3, IL-10, IL-17 and INF-γ) and those associated with no significant change from discharge to 1 year (i.e., Kyn, IDO, HMGB1, uric acid, TNFα, Trp, IL-7, and RvD1) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Variation in circulating biomarkers from ICU discharge to one year. *TNF* tumor necrosis factor, *IL* interleukin, *IFN* interferon, *IDO* indoleamine2,3 dioxygenase, *HMGB1* high mobility group box 1 protein, *PD-1* programmed cell death protein-1, *RvD* resolvins

### Association between biomarkers and prognosis {#Sec14}

The extent of inflammation correlated with ICU outcomes. ICU non-survivors had higher levels of cluster 1 biomarkers (IL-17, Kyn, and IDO activity) and cluster 2 biomarkers (HMGB1 and caspase 3), while their IL-10 levels (cluster 3) were lower at admission (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). At ICU discharge, no cluster 1 biomarker was associated with 1-year mortality. Interestingly, the cell damage marker (HMGB1) and the resolving RvD5 levels were higher and lower, respectively, at ICU discharge in the 1-year non-survivors (Fig. [3](#Fig3){ref-type="fig"}, Table [4](#Tab4){ref-type="table"}). The area under the receiver operating characteristic (ROC) curves for these two biomarkers were 0.743 (0.5--0.937) and 0.715 (0.507--0.903) for HMGB1 and RvD5, respectively. After adjustment for SOFA score at admission, both biomarkers were independently associated with 1-year outcome (odds ratios 1.32 (1.07--1.61) (*p* = 0.009) and 0.58 (0.37--0.90) (*p* = 0.016) for an increase of one unit of HMGB1 and RvD5, respectively).Fig. 3Levels of biomarkers according to patients' outcomes. Red stars indicate a significant difference in biomarker level between survivors and non-survivors. **a** biomarkers of inflammation, **b** biomarkers of damage and apoptotic cells, **c** biomarkers of sepsis induced immunosuppression and resolution of inflammation. *TNF* tumor necrosis factor, *IFN* interferon, *IDO* indoleamine2,3 dioxygenase, *HMGB1* high mobility group box 1 protein, *RvD* resolvinsTable 3Association between biomarkers levels and outcomeIn-ICU survivors\
*n* = 55In-ICU non survivors *n* = 31*p* valueCirculating biomarkers at ICU admissionTNF alpha (pg/mL)64.5 (40.4--98.8)86.2 (52.8--119.8)0.23IL-6 (pg/mL)2286.7 (1342--3013.9)2167 (1685.5--3317)0.59IFN-gamma (pg/mL)19 (16.9--26.9)17.4 (16.8--20.2)0.43IL-17 (pg/mL)20.1 (16.7--28.3)29.3 (21.4--40.2)0.002Tryptophan (μmol/L)48 (38.8--59.8)46.4 (35.4--59.8)0.56IDO (%)12.5 (9--16.2)24.7 (15.2--32.5)\<0.0001Kynurenine (μmol/L)5.8 (4.1--8.4)13.3 (6.3--14.2)\<0.0001Uric acid (μmol/L)318 (262.5--377)293 (239.5--351.5)0.14HMGB1 (ng/mL)17 (16.1--18.9)32.6 (21.1--43.7)\<0.0001Caspase-3 (pmol/min/mL)4.9 (2.2--8.1)9.4 (6--13.3)\<0.0001PD-1 (ng/mL)0 (0--0)0 (0--0)-IL-10 (pg/mL)6.2 (4.5--8.7)4.1 (2.4--5.2)0.001RvD1 (pg/mL)0.8 (0.5--1)0.7 (0.4--1)0.4RvD5 (pg/mL)0 (0--0)0 (0--0)-IL-7 (pg/mL)1.9 (1.3--3.1)2.6 (1.7--3.6)0.14Results are expressed as median (interquartile range); *p* values are from the Wilcoxon rank test*Abbreviations*: *TNF* tumor necrosis factor, *IL* interleukin, *IFN* interferon, *IDO* indoleamine2,3 dioxygenase, *HMGB* high mobility group box 1 protein, *PD* programmed cell death, *RvD* resolvinsTable 4Association between biomarkers levels and outcomeOne-year survivors\
*n* = 46One-year non survivors *n* = 9*p* valueCirculating biomarkers at ICU dischargeTNF alpha (pg/mL)35.2 (21--54)48 (30--72.7)0.25IL-6 (pg/mL)59 (30.5--83)86 (51--89.3)0.26IFN-gamma (pg/mL)10 (7.4--13.8)11.6 (9--15.1)0.24IL-17 (pg/mL)70.8 (55.9--79.5)78.7 (55.7--103.1)0.13Tryptophan (μmol/L)35.7 (29.2--40.9)34.1 (31.5--36.1)0.67IDO (%)13.7 (9.2--18.7)12.7 (8.4--22.7)0.7Kynurenine (μmol/L)5.1 (3.4--6.1)4.6 (2.1--7.2)0.55Uric acid (μmol/L)317.5 (273.5--397.2)376 (321--414)0.35HMGB1 (ng/mL)7 (5.5--9.3)11.8 (8.8--23)0.023Caspase-3 (pmol/min/mL)3.8 (2.5--4.9)5.3 (3.7--18.7)0.13PD-1 (ng/mL)0.8 (0.6--1)0.4 (0--0.8)0.057IL-10 (pg/mL)13.8 (11.6--15.5)12.8 (11.6--14.4)0.33Rv-D1 (pg/mL)5 (3.9--5.8)4.8 (4.4--6.7)0.36Rv-D5 (pg/mL)4.9 (4--6.1)3.8 (0--4.8)0.044IL-7 (pg/mL)5.8 (4.8--7.1)5.5 (5.2--49.3)0.77Results are expressed as median (interquartile range); *p* values are from the Wilcoxon rank test*Abbreviations*: *TNF* tumor necrosis factor, *IL* interleukin, *IFN* interferon, *IDO* indoleamine2,3 dioxygenase, *HMGB* high mobility group box 1 protein, *PD* programmed cell death, *RvD* resolvins

Clinical signs at baseline and markers levels variations {#Sec15}
--------------------------------------------------------

Correlation with SOFA score at admission and variations in biomarker levels from discharge to 1 year are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2. There was no significant correlation with variation, except for moderate correlation between variation in kynurenine and the SOFA score (rho (95% CI)) = 0.23 (-0.04; - 0.47)).

Discussion {#Sec16}
==========

This study aimed to explore the evolution of the immune profile of patients admitted to the ICU for septic shock of abdominal origin up to 1 year after ICU discharge. Thus, we studied several plasma biomarkers at ICU admission, discharge and 12 months after ICU discharge. The primary result was a protracted immune disturbance 1 year after ICU discharge, Several markers had persistent abnormal levels; IL-6, Trp, Kyn and IDO in cluster 1, caspase 3 in cluster 2, and PD-1 and IL-7 in cluster 3 were significantly elevated. The proportion of patients having at least one abnormal biomarker in only one cluster was 9% (*n* = 4), whereas 70% (*n* = 32) had abnormal values of biomarkers within all three clusters.

The study of the variations from ICU discharge to 1 year identified two types of biomarkers of change: those associated with a significant decrease (i.e., PD-1, RvD5, IL-6, caspase 3, IL-10, IL-17 and INF-γ) and those associated with no significant change from discharge to 1 year (i.e., Kyn, IDO, HMGB1, uric acid, TNFα, Trp, IL-7, and RvD1).

We also explored the relationship between the biomarker levels and patient outcomes. At admission, the patients who died in the ICU had higher levels of inflammatory biomarkers (IL-17, Kyn, IDO) and cell damage biomarkers (HMGB1, caspase 3), while levels of IL-10, an anti-inflammatory cytokine, were lower compared to levels in the survivors. At ICU discharge, HMGB1 was higher and RvD5 was lower in the patients who died in the first year after sepsis compared to the survivors. These results highlight the long-term sequelae of septic insult.

It is now well-recognized that patients with sepsis continue to have the worst outcomes in the months and years after hospital discharge; there is growing interest in the study of long-term sepsis outcomes. Several reports have shown that sepsis survivors are likely to develop chronic illness, such as cardiovascular \[[@CR8]\], pulmonary \[[@CR9]\], and renal \[[@CR10]\] disease, or depression \[[@CR11]\]. Our study findings align with those of prior studies. Persistent inflammation, with elevated levels of IL-6 and IL-10, was found at hospital discharge after community-acquired pneumonia \[[@CR12]\].

Little is known about the disease mechanistic pathways involved in this phenomenon. To explore this pathogenesis, we conducted a wide study of the immune profile over time. We did not limit our work to inflammation but extended it to the markers of cell damage, apoptosis, immunosuppression and resolution of inflammation, to paint a picture of an evolving mechanism beginning with tissue damage that causes inflammation, followed by a healing process to restore homeostasis.

There is a discrepancy between the clinical picture of "cured" patients who are eligible for ICU discharge (for whom dampening of the inflammation is expected to be rather quick) and evidence of persistent sickness with a damaged immune response that remains long after the event. This discrepancy emphasizes the absence of a homeostasis reset after curing visible signs of sepsis, which could lead to the development or acceleration of chronic diseases.

Most of the studied markers tended to return (more or less) to their normal levels. The clinical significance of moderately elevated IL-6, Kyn, and IDO is questionable. In addition, long-term mild inflammation has been associated with bad outcomes in various diseases, such as cancer \[[@CR27]\] or atherosclerosis \[[@CR28]\]. Trp and its metabolites play an important role in the immune balance between response to pathogen and tolerance \[[@CR18]\]. Trp, an essential amino-acid, is the serotonin precursor and Trp deficits are correlated with impaired T cell proliferation \[[@CR29]\] and enhancement of cellular stress response. The intracellular enzyme, IDO degrades Trp and produces Kyn-derived metabolites. IDO is stimulated by lipopolysaccharide (LPS), TNFα, IFN-γ, transforming growth factor (TGF)ß and activation of toll-like receptor (TLR)3, TLR4, TLR7, and TLR8 \[[@CR30]\]. After major trauma, increased plasma Kyn and Kyn-Trp ratios are early indicators for sepsis development \[[@CR31]\]. Kyn directly damages tissues and organs, induces dysregulation of vascular tone, and is a key factor in the communication between the nervous and immune systems. Kyn metabolites such as kynurenic and quinolinic acids could also impair neurological systems \[[@CR32]\].

Trp levels increased from ICU discharge to 1 year, and while this increase is supposed to be beneficial, the levels remained below the control group values at 1 year. Low Trp levels are reportedly associated with cancer \[[@CR33]\], cardiovascular disease \[[@CR34]\], and depression \[[@CR35]\]. Integrative studies using several immuno-metabolic markers and clinical score were found to be useful to predict the risk but could also help in the understanding of the pathophysiology of septic derangements \[[@CR36], [@CR37]\]. PD-1, which has an immunosuppressive function as a negative regulator of T cells by preventing their proliferation and altering their bacterial clearance, was still elevated at 1 year, although this biomarker level dramatically decreased (80%) after ICU discharge. Together, these findings raise the hypothesis of a protracted immunodeficiency state.

The elevated levels of IL-7 were surprising. This report is the first to focus on circulating IL-7 at 1 year after septic shock and indicates an ongoing immune process. IL-7 is thought to be a beneficial mediator after acute inflammation. It has an anti-apoptotic effect on lymphocytes and has stimulating effects on B lymphocytes and natural killer cells \[[@CR38]\]. These findings raise the question of a lasting immune healing response and may indicate a possible treatment for post-sepsis immune dysfunction, because IL-7 administration has already been proposed for immune depression in HIV infection \[[@CR39]\]. The effect of IL-7 on long-term outcomes must be further investigated.

Limitations of the study {#Sec17}
------------------------

Our cohort was monocentric and relatively small, in terms of the high number of studied biomarkers. It is, therefore, possible that some of our conclusions are erroneous and must be confirmed in larger prospective multicentric studies. We also studied a specific group of patients (i.e., those with septic shock of abdominal origin), which limits the generalizability of our results. The choice of patients with septic shock and not patients with severe sepsis was based on the hypothesis that the sickest patients have worse symptoms and would be more easily identified among a limited number of subjects. We had to choose a limited number of biomarkers. We cannot exclude that other molecules could have been of interest. In addition, we did not study cell function or number at 1 year. Our study was focused on the variation of the biomarkers levels during and after ICU admission and discharge. The association between the biomarkers levels and prognosis was a secondary objective and therefore no sample calculation was made. Conclusions that can be drawn from these data are limited.

Source control may impact the kinetics of the measured mediators. All our patients had the same type of source control (i.e., surgery). Despite the fact that the time and type of surgery could play a role in patient disease severity, we believe that they would marginally impact the levels of mediators at the studied time points. More important, we do not have any data on the relationships between the biomarker levels and outcomes other than death. Such data were, unfortunately, not recorded. The control group was not matched on age, sex, and comorbidities, limiting the interpretation of the results. Another limitation is that we could not assess the levels of biomarkers in our patients before they had septic shock; these could have been abnormal before the onset of sepsis. There is a long gap between ICU discharge and 1 year. The exclusion of nine patients who died during this period may bias the results. If measurements were obtained at 3 and 6 months, more abnormalities may have been detected.

Conclusion {#Sec18}
==========

The present study underscores the notion of a long-lasting, immune illness disorder after septic insult. It also suggests the need to examine the immune and cell damage responses not only at the beginning of ICU admission but also at ICU discharge and much later, up to 1 year.

A better understanding of those disorders might help to delineate groups of patients with different manifestations of acute septic illness. Follow up should be performed to identify specific and appropriate treatments, even long after the acute septic insult. For example, in our study, the persistence of high circulating PD-1 may indicate treatment by anti-PD1. Likewise, the beneficial high levels of circulating IL-7 in the 1-year survivors may indicate the importance of monitoring these levels and considering administration of this beneficial mediator following ICU care. Obviously, further studies are needed to confirm those hypotheses.

Additional file
===============

 {#Sec19}

Additional file 1:Details on biomarker clusters. **Table S1.** Four clusters of circulating mediators of immune response. **Table S2.** Correlation between biomarkers at 1 year and SOFA score at admission. (DOCX 60 kb)
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